{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001005587"],"host":["EGA"],"description":["EGA study EGAS00001005587"],"dataset_title":["SAFIR02_Agilent"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["Therapy, Breast Carcinoma, Human Mammary Neoplasm, primary breast cancer, Carcinoma, malignant tumor of the breast, Genomics, Breast Carcinomas, \"breast neoplasm\" EXACT [MTH:120], Comparative, Neoplasms, mammary neoplasm, Mammary Cancers, Human Mammary Neoplasms, Functional Genomics, Tumor, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Client, Human, Breast Malignant Neoplasm, Breast Malignant Tumor, Structural, microarray., \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], Mammary Carcinomas, Breast Tumor, Functional, Neoplasm, Human Mammary Carcinoma, \"mammary tumor\" EXACT [CSP2005:2016-0671], NOS, breast tumor, cancer of the breast, Malignant Neoplasm of Breast, Carcinomas, BC, treatment, Mammary Neoplasms, malignant neoplasm of breast, Human Mammary, Breast Neoplasm, Mammary Neoplasm, Comparative Genomics, Mammary Carcinoma, Human Mammary Carcinomas, Cancers, \"mammary neoplasm\" RELATED [], Treatments, Cancer of the Breast, metastatic, Patient, breast cancer, Therapeutic, cancer of breast, Malignant Tumor of Breast, Clients, Mammary, Mammary Cancer, Breast Tumors, Breast Cancer, disease management, Breast Malignant Tumors, Therapies, Structural Genomics, Cancer of Breast, Treatment, Breast, mammary cancer, cancer, mammary tumor, Breast Malignant Neoplasms, breast, Tumors, Cancer"],"description_synonyms":["Erbb-2, Voltage-gated calcium channel subunit alpha Cav1.2, malignant tumor of the breast, scale tissue, Breasts, Materials, tumor suppressor, acetylglucosaminyltransferase-like protein, Mbp1, mammary neoplasm, Lactiferous gland, Human Mammary Neoplasms, sci, Tumor, glandula mammaria, CD340, cell cycle regulator, Kiaa3023, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], Calcium channel, HOW, How, cancer of the breast, Transforming, myd, l(3)j5D5, 24B, treatment, BC, Mammary Neoplasms, malignant neoplasm of breast, like-acetylglucosaminyltransferase, Comparative Genomics, plant peltate hair, stru, Human Mammary Carcinomas, Mbp-1, l(3)S053606, CG10293, l(3)j5B5, Transforming Genes, malignant neoplasm, cancer of breast, disease management, Therapies, DOCK180., Malignancies, mammary cancer, Breast Malignant Neoplasms, Tumors, mamma, Therapy, Carcinoma, 0904/17, Genomics, \"breast neoplasm\" EXACT [MTH:120], gyltl1b-b, Comparative, MELC-CC, MLN19, Functional Genomics, CED-5, Benign, SZ1, Maintenance, MDDGA6, Hch, mKIAA0609, Lobe of mammary gland, Genetic Materials, Chemotherapy, NOS, KIAA0609, Malignant Neoplasm of Breast, Genetic Material, acetylglucosaminyltransferase-like 1A, c-neu, Carcinomas, AI662014, fg, Cchl1a1, gyltl1b, mdc1d, Benign Neoplasms, DmelCG10379, \"mammary neoplasm\" RELATED [], LARGE_HUMAN, Treatments, Malignant Neoplasms, time before disease progression, MLN 19, MDC1D, metastatic, Oncogene, enr, Patient, breast cancer, Material, Breast Tumors, Breast Malignant Tumors, TKR1, Cistron, anon-EST:Liang-2.39, isoform 1, cancer, mammary region, primary breast cancer, P62, Neoplasms, peltate hair, Benign Neoplasm, number, Gene, Mammary Cancers, Malignant, LARGE1, presence, Cav1.2, AW122239, froggy, Gyltl1a, Chemotherapies, Human, Breast Malignant Tumor, Structural, L type, RRG6, Breast Tumor, dock180, Functional, \"mammary tumor\" EXACT [CSP2005:2016-0671], breast tumor, HER-2/neu, Human Mammary, Transforming Gene, Genetic, l(3)s2612, Malignancy, Mammary Neoplasm, MDDGB6, HER-2, Dm MBC, Mammary Carcinoma, Maintenance Chemotherapies, Mbc, MBC, mammary part of chest, LARGE, Cancer of the Breast, Neoplasias, BPFD#36, GEP6, Malignant Tumor of Breast, Clients, Mammary, Mammary Cancer, heterogeneity, DmelCG10293, Breast, mammary tumor, Mouse brain class C, Cancer, Neu, NEU, Dock180, Breast Carcinoma, Human Mammary Neoplasm, Breast Carcinomas, Malignant Neoplasm, clone 2.39, HER-2|neu, mKIAA3023, qkr, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Cistrons, l(3)S090417, Brustdruese, Client, cardiac muscle, Breast Malignant Neoplasm, count in organism, MT, Mammary Carcinomas, KH93F, Neoplasm, NGL, Human Mammary Carcinoma, scales, who, CG10379, primary cancer, Breast Neoplasm, Genes, scale, c-erbB2, Lobe of breast, patient, Cancers, Who/How, MBC/DOCK180, alpha-1 polypeptide, malignant tumor, Su(rac)1, like-glycosyltransferase, Therapeutic, Breast Cancer, cardinality, qkr[93F], Treatment, Cancer of Breast, Structural Genomics, D930026N18Rik, Neoplasia, HER2, breast, glycosyltransferase-like protein LARGE1"],"additional_accession":[]},"is_claimable":false,"name":"Genomics to select patients with metastatic breast cancer for targeted therapy (microarray agilent)","description":"Cancer progression is driven in part by genomic alterations located in oncogenes or tumor suppressor genes. The genomic characterization of cancers has shown a large interpatient heterogeneity regarding the driver alterations, leading to the concept that generating a genomic profiling by multigene sequencing in patients with cancer could allow selecting effective targeted therapies. While this concept has been broadly implemented in daily practice, there is no evidence that such approach improves patient outcome, and how to optimally select the therapy to administer. A genomic profiling using next generation sequencing and copy number analyses was performed 1462 patients with Her2-non overexpressing metastatic breast cancer included in SAFIR02 Breast trial. 238 of these patients were randomized in two trials between a targeted therapy matched to genomic alteration and a maintenance chemotherapy. The trial shows that targeted therapies matched to genomics improves progression free survival (PFS) when genomic alterations are classified level I/II according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) (adjusted HR: 0.41, 90% CI: 0.27-0.61, p<0.001), but not when alterations are classified beyond level II (unadjusted HR: 1.15, 95% CI: 0.76-1.75). This trial provides evidence that the treatment decision led by genomics should be driven by a framework of target actionability in patients with mBC.","dates":{"updated":"2021-11-16 15:43:14"},"accession":"EGAS00001005587","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00010002243","EGAC00001002293"]}}